Skip to main content

Review of the Fialuridine (FIAU) Clinical Trials

View Cover

Purchase Options
Purchase Options MyNAP members save 10% online. Login or Register



In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.


Suggested Citation

Institute of Medicine. 1995. Review of the Fialuridine (FIAU) Clinical Trials. Washington, DC: The National Academies Press.

Import this citation to:

Publication Info

280 pages | 8.5 x 11
  • Paperback: 978-0-309-05279-5
  • Ebook: 978-0-309-17661-3

Table of Contents

skim chapter
Front Matter i-x
Executive Summary 1-15
Introduction 16-19
Clinical Trials 20-33
Hepatitis B and Other Viral Diseases 34-41
Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center 42-50
Oclassen Clinical Trial R89-001-01 51-54
Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031) 55-60
Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213) 61-65
Eli Lilly Trial H3X-MC-PPPA 66-69
Eli Lilly Trial H3X-MC-PPPG 70-72
Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031) 73-89
Summary of Patient Interviews 90-92
Overall Assessment of the Trials 93-97
Recent Studies of FIAU Toxicity 98-103
Review of the FDA Task Force Report 'Fialuridine: Hepatic and Pancreatic Toxicity' 104-120
Review of 'Report to the Advisory Committee to the Director, National Institutes of Health' 121-132
FDA-Proposed Changes to the Code of Federal Regulations 133-142
Ancillary Issues Raised During the Period Following The H3X-MC-PPPC Trial 143-149
Conclusions and Recommendations 150-154
Appendix A: Chronology of FIAU/FIAC Clinical Trials 155-164
Appendix B: Bibliography and References 165-177
Appendix C: Agendas from the Three Committee Meetings 178-183
Appendix D: Informed Consent Documents 184-243
Appendix E: Example of Oclassen Fax Data Summaries 244-245
Appendix F: FIAC and FIAU Preclinical Toxicity Studies 246-250
Appendix G: Patient Summaries, Lilly Trial H3X-MC-PPPA 251-255
Appendix H: Statistical Analysis of Mortality in the FIAU/FIAC Clinical Trials 256-265
Glossary 266-269

Copyright Information

The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:

  • Republish or display in another publication, presentation, or other media
  • Use in print or electronic course materials and dissertations
  • Share electronically via secure intranet or extranet
  • And more

For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.

Click here to obtain permission for Review of the Fialuridine (FIAU) Clinical Trials.

Translation and Other Rights

For information on how to request permission to translate our work and for any other rights related query please click here. Customer Service

For questions about using the service, please contact:

Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)

Loading stats for Review of the Fialuridine (FIAU) Clinical Trials...